

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Filgotinib for treating axial spondyloarthritis ID6594

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

Stakeholder noted that it is important to consider that oral medication may be more appropriate for those with particular disabilities, such as learning difficulties, or those who are not able to inject or use a pen.
--

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---|

Some people with axial spondyloarthritis may have learning difficulties or are not able to inject or use a pen. Disability is protected characteristics under the Equality Act 2010, but because the committee recommendation would not restrict access to treatment for some people over others, these are not considered potential equalities issues.

- | |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No.

Approved by Principal Technical Adviser (name): Lizzie Walker

Date: 02/03/2026